ClinicalTrials.gg
Not yet recruitingNCT07591532Beyond BCYUpdated May 15, 2026

Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA

An observational study in Breast Cancer and Breast Cancer and Pregnancy, sponsored by Jules Bordet Institute. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Jules Bordet Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,200
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.

Started
2026
with 2 others
Observational
4 of 42
2 open now
Registered
42nd of 42
by date

Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is one of 3 that started in 2026, is one of 4 observational ones, and was the 42nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Breast Neoplasms by Jules Bordet Institute, or all of them as a file.
02

Study summary

The present study aims to refine the understanding of the prognostic impact of pregnancy after breast cancer in young women harboring germline pathogenic variants in breast cancer susceptibility genes other than BRCA

Read the detailed description

This retrospective, multicenter, observational study aims to evaluate the prognostic impact of pregnancy after breast cancer diagnosis in young women harboring germline pathogenic variants in breast cancer susceptibility genes other than BRCA1/2, including TP53, PALB2, PTEN, CDH1, STK11, CHEK2, ATM, BARD1, RAD51C, and RAD51D.

Although pregnancy after breast cancer has been shown to be safe in the overall population of young breast cancer survivors and in carriers of BRCA1/2 pathogenic variants, evidence remains limited for patients with pathogenic variants in other breast cancer susceptibility genes. This knowledge gap represents a relevant unmet need in oncofertility counseling and survivorship care.

The study will include patients diagnosed with stage I-III invasive breast cancer at age 40 years or younger between January 2000 and December 2025. The primary objectives are to assess the prognostic impact of pregnancy after breast cancer diagnosis and to evaluate the cumulative incidence of pregnancy in this population. Secondary objectives include the assessment of pregnancy, fetal, and obstetrical outcomes, the safety of assisted reproductive technology procedures, patterns of care including risk-reducing surgeries, survival outcomes according to clinicopathologic and genetic subgroups, and the occurrence of second primary malignancies.

Data will be collected retrospectively from participating centers within the Beyond BRCA BCY Collaboration.

03

Conditions studied

  • Breast Cancer
  • Breast Cancer and Pregnancy

Browse trials for

Keywords

  • breast cancer
  • Pregnancy
  • Young Women
  • Hereditary Breast Cancer
  • Germline Pathogenic Variants
  • Breast Cancer Susceptibility Genes
  • Oncofertility
  • TP53
  • PALB2
  • PTEN
  • CDH1
  • STK11
  • CHEK2
  • ATM
  • BARD1
  • RAD51C
  • RAD51D
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Young women diagnosed at age 40 years or younger with stage I-III invasive breast cancer between January 2000 and December 2025 and harboring a germline pathogenic variant in a breast cancer susceptibility gene other than BRCA1/2, including TP53, PALB2, PTEN, CDH1, STK11, CHEK2, ATM, BARD1, RAD51C, and RAD51D.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stage I-III invasive breast cancer between January 2000 and December 2025
  • Age at breast cancer diagnosis ≤40 years
  • Germline pathogenic variant in at least one of the following breast cancer susceptibility genes other than BRCA: TP53, PALB2, PTEN, CDH1, STK11, CHEK2, ATM, BARD1, RAD51C, or RAD51D

Exclusion criteria

Exclusion Criteria:

  • Known germline pathogenic variant in breast cancer susceptibility genes without a diagnosis of invasive breast cancer
  • Diagnosis of ovarian cancer or other without a prior history of invasive breast cancer
  • Diagnosis of invasive breast cancer with germline variants of uncertain significance in breast cancer susceptibility genes
  • De novo stage IV breast cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pregnant cohort

    Women with one or more pregnancies any time after breast cancer diagnosis

  • Non-pregnant cohort

    Women with no subsequent pregnancies after breast cancer diagnosis

06

What researchers measure

Primary outcomes

  1. Cumulative Incidence of Pregnancy After Breast Cancer Diagnosis

    Time frame: Up to 20 years from breast cancer diagnosis

  2. Invasive Disease-Free Survival (iDFS)

    Time frame: Up to 20 years from breast cancer diagnosis

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — De-identified individual participant data may be shared upon reasonable request, subject to submission of a formal research proposal to the study Principal Investigators and review and approval by the study leadership. Any data sharing will be subject to applicable ethics approvals, data transfer agreements, local institutional requirements, and data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 15, 2026
StartEst.
Jun 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2030
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07591532
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jun 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 15, 2026

Study contacts

Eva Blondeaux, MD
Contact
BCYcollaboration@aomliguria.it
+39 010 555 8502
Luca Arecco, MD
Contact
BCYcollaboration@aomliguria.it
Matteo Lambertini, MD, PhD
principal investigator · IRCCS Azienda Ospedaliera Metropolitana
Evandro de Azambuja, MD, PhD
principal investigator · Jules Bordet Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion